Meeting
2022 ASCO Annual Meeting
Association of antibiotic therapy and treatment efficacy in urothelial cell carcinoma patients receiving immune checkpoint inhibitors.
Authors
Avery Braun
Einstein Healthcare Network, Philadelphia, PA
Avery Braun , Mengying Deng , Elizabeth A. Handorf , Philip Abbosh
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Genitourinary Cancer—Kidney and Bladder
Track
Genitourinary Cancer—Kidney and Bladder
Sub Track
Urothelial Cancer - Advanced/Metastatic Disease
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr 4578)
DOI
10.1200/JCO.2022.40.16_suppl.4578
Abstract #
4578
Poster Bd #
69
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
Association of antibiotic therapy and treatment efficacy in patients with renal cell carcinoma receiving immune checkpoint inhibitors.
First Author: Avery Braun
Poster
2024 ASCO Genitourinary Cancers Symposium
PEMBROBLAD: Real world effectiveness and safety of immune checkpoint inhibitors in patients with advanced urothelial carcinoma with histological variants.
First Author: Karim Amrane Sr.
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Zanzalintinib (XL092) plus atezolizumab versus regorafenib in previously treated MSS/MSI-low metastatic colorectal cancer (mCRC): The randomized phase 3 STELLAR-303 study.
First Author: Anwaar Saeed
Poster
2023 ASCO Annual Meeting
The effect of antibiotic (Abx) use on immune checkpoint inhibitor (ICI) efficacy in patients (pts) with metastatic urothelial carcinoma (mUC) in a real-world setting.
First Author: Ubenthira Patgunarajah